Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
M A Sekeres1, A S Swern2, P Fenaux3
1Leukemia Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
Blood Cancer Journal
|August 30, 2014
Abstract
No abstract available in PubMed .


